Chimeric Therapeutics Ltd C.CHM

Primary Symbol: CHMMF

Healthcare Biotechnology

Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company. The Company is focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its pipeline includes CHM 1101 and CHM 2101. Its CHM 1101 (CLTX CAR-T) is a CAR-T therapy developed for the treatment of patients with solid tumors. CHM-1101 is being studied in a Phase 1B clinical trial in recurrent/ progressive glioblastoma. CHM 2101 is a third generation CDH17 CAR T, which is in preclinical development with a planned Phase I clinical trial in neuroendocrine tumors, colorectal, pancreatic and gastric cancer. Its pipeline also includes the CORE-NK platform, a clinically validated, off-the-shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). The Company is also focused on the development of NK and CAR NK assets with plans for Phase 1B clinical trials in solid tumors and blood cancers.

OTCPK:CHMMF - Post by User

Chimeric Therapeutics Ltd > CEO selling shares

<< Previous

Bullboard Posts

Next >>

Comment by fredskion Jul 19, 2020 11:03am

148 Views

Post# 31287302

RE:RE:CEO selling shares

You are not telling the whole story here :

https://ceo.ca/api/sedi?symbol=CHM&amount=&transaction=&insider=kott

And btw you are making the same investment mistake than IPA when you could've bought it @ .45 now $1.50

Buy low sell high is how Pros do. Buying High in the hopes of selling higher like you is how you make your network continuously lose money.

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security